AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016

New evidence to be presented includes pivotal Phase III data on benralizumab 30 August 2016 AstraZeneca will present new data from its growing respiratory portfolio and pipeline at the annual meeting of the European Respiratory Society (ERS) International Congress, 3-7 September 2016 in London, UK. The breadth and depth of science behind the portfolio and pipeline are reflected in the 38 accepted abstracts including nine oral presentations focused on unmet medical needs in asthma and chronic obstructive pulmonary disease (COPD). Highlights will include full Phase III data for benralizumab, AstraZeneca’s first respiratory biologic, as well as new evidence for dual bronchodilation in COPD and for Symbicort in both COPD and asthma. Sean Bohen, Executive Vice-President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The data presented at ERS reflect the breadth of our scientific research in chronic respiratory disease and our progress in delivering the next generation of respiratory therapies. We are particularly excited to share the full Phase III data from the SIROCCO and CALIMA trials on benralizumab in severe asthma, where it is critical to improve outcomes for patients.” Phase III data on benralizumab Data from two pivotal Phase III trials of benralizumab in severe asthma will be presented for the first time ( abstracts #OA4832 and #OA1969) . Achieving maximum bronchodilation for COPD patients New data will be presented on: A Duaklir (aclidinium/formoterol) study showing reduced deterioration in COPD compared to monotherapies and placebo (abstract #PA301) The benefit of Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) over a 24-hour period versus tiotropium bromide inhalation spray and placebo (abstract #PA994) The effect of dual bronchodilation in all the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages (abstracts #PA310 and #PA992 ) Symbicort as maintenance and reliever therapy Ten abstracts including new data on the benefit of Symbicort maintenance and reliever therapy in adolescents (abstract #PA4903) and real-world evidence of the disease burden in mild asthma (abstract #PA4590). NOTES TO EDITORS About AstraZeneca in Respiratory Disease Respiratory disease is one of AstraZeneca’s main therapy areas, and we have a growing portfolio of medicines that reached more than 17 million patients in 2015. Our aim is to transform asthma and COPD treatment through inhaled combinations at the core of care, biologics for the unmet needs of specific patient populations, and scientific advancements in disease modification. We are building on a 40-year heritage in respiratory disease, and our capability in inhalation technology spans both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs), as well as our unique Co-Suspension TM Delivery Technology. Our research is focused on four key biological pathways: eosinophilic disease, Th2-driven disease, epithelial-driven pathobiology and autoimmunity. About MedImmune MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: http://www.astrazeneca.com/ CONTACTS Media Enquiries Neil Burrows UK/Global +44 203 749 5637 Vanessa Rhodes UK/Global +44 203 749 5736 Karen Birmingham UK/Global +44 203 749 5634 Rob Skelding UK/Global +44 203 749 5821 Jacob Lund Sweden +46 8 553 260 20 Michele Meixell US +1 302 885 2677 Investor Enquiries UK Thomas Kudsk Larsen +44 203 749 5712 Craig Marks Finance, Fixed Income, M&A +44 7881 615 764 Nick Stone Respiratory & Autoimmunity +44 203 749 5716 Henry Wheeler Oncology +44 203 749 5797 Christer Gruvris Infection & Neuroscience +44 203 749 5711 US Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970 Mitch Chan Oncology +1 240 477 3771 Dial / Toll-Free +1 866 381 7277

The release as fetched from its publisher. astrazeneca.com ↗